The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

We recently compiled a list of the 10 Firms Fall Amid Disappointing Earnings Performance. In this article, we are going to ...

It has been almost five years since the COVID-19 pandemic happened and close to two years since President Marcos lifted the public health emergency in the country. And yet, costly irregularities, ...

Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ ... visibility into the sales trajectory of its respiratory vaccine business. Moderna (NASDAQ:MRNA) earlier projected ...